Duration of systemic therapy in patients with metastatic EGFR-mutated non-small cell lung cancer and brain metastases

Michael Yan, Michael Tjong, Natalie Coburn, Lena Nguyen, Arjun Sahgal, Alexander V Louie, Ambica Parmar · 2026

Read Duration of systemic therapy in patients with metastatic EGFR-mutated non-small cell lung cancer and brain metastases by Michael Yan, Michael Tjong, Natalie Coburn, Lena Nguyen, Arjun Sahgal, Alexander V Louie, Ambica Parmar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263819.txt.

Description

Michael Yan and colleagues used in 2026 Ontario health records to compare two targeted pills in lung cancer that had spread to the brain. Patients with EGFR-mutated metastatic disease received either osimertinib or the older gefitinib as first treatment, alongside brain radiation. Their database covered care from 2007 to 2024, and 481 patients met the study's rules.

Osimertinib patients stayed on first-line therapy about twice as long, a median near thirteen months against six. Control over brain disease also lasted longer, and median survival roughly doubled to about twenty-five months. Matching patients on background factors left all three advantages standing. The authors say real-world practice confirms the trial-based preference for the newer drug when the brain is involved. They note treatment duration itself as a meaningful real-world endpoint.

Catalog record

CREATORMichael Yan, Michael Tjong, Natalie Coburn, Lena Nguyen, Arjun Sahgal, Alexander V Louie, Ambica Parmar
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE22 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13263819

Browse the full library · About the Tower of Babel